secondary malignancies	occurs after	chemotherapy
secondary malignancies	occurs after	radiotherapy
secondary malignancies	associated with	alkylating agents
secondary malignancies	associated with	topoisomerase II inhibitors
secondary malignancies	associated with	hematopoietic stem cell transplant
secondary malignancies	associated with	radiation exposure
secondary malignancies	associated with	immune suppression
secondary malignancies	associated with	genetic predisposition
secondary malignancies	associated with	chronic inflammation
secondary malignancies	increases	mortality
secondary malignancies	increases	healthcare costs
secondary malignancies	diagnosed by	bone marrow biopsy
secondary malignancies	diagnosed by	imaging studies
secondary malignancies	diagnosed by	histology
secondary malignancies	treated with	chemotherapy
secondary malignancies	treated with	radiotherapy
secondary malignancies	treated with	surgery
secondary malignancies	screened by	complete blood count
secondary malignancies	screened by	imaging surveillance
secondary malignancies	risk factor for	second primary malignancy
secondary malignancies	most common in	elderly
secondary malignancies	most common site	bone marrow
therapy-related AML	is a	secondary malignancy
therapy-related AML	associated with	prior chemotherapy
therapy-related AML	prognosis worse than	de novo AML
therapy-related AML	diagnosed by	bone marrow biopsy
therapy-related MDS	is a	secondary malignancy
therapy-related MDS	associated with	alkylating agents
therapy-related MDS	can progress to	AML
second primary malignancy	is a	concept
second primary malignancy	arises after	cancer therapy
second primary malignancy	is a	complication of cancer treatment
second primary malignancy	surveillance with	imaging studies
second primary malignancy	management with	surgery
second primary malignancy	management with	chemotherapy
second primary malignancy	management with	radiotherapy
second primary malignancy	prognosis with	treatment success
second primary malignancy	risk factor for	mortality
second primary malignancy	incidence in	cancer survivors
secondary malignancies	occur in	pediatric populations
secondary malignancies	more likely after	autologous transplant
secondary malignancies	more likely after	allogeneic transplant
secondary malignancies	common in	long-term cancer survivors
secondary malignancies	associated with	chemotherapy dose exposure
secondary malignancies	associated with	concurrent radiation therapy
bone marrow involvement	accompanies	secondary malignancies
imaging surveillance	detects	secondary malignancies
bone marrow biopsy	confirms	secondary malignancies
complete blood count	monitors	secondary malignancies
survivorship care	includes	secondary malignancies screening
genetic predisposition	increases	secondary malignancies risk
immune suppression	predisposes to	secondary malignancies
smoking	associated with	secondary malignancies
viral infection	associated with	secondary malignancies
environmental exposure	associated with	secondary malignancies
family history	associated with	secondary malignancies
cytogenetic abnormality	associated with	therapy-related AML
p53 mutation	associated with	therapy-related AML
age at diagnosis	influences	risk of secondary malignancies
sex	influences	risk of secondary malignancies
recurrent cancer	associated with	secondary malignancies
cancer survivors	at risk for	second primary malignancies
hematologic toxicity	signals	secondary malignancies
anemia	common in	secondary malignancies
thrombocytopenia	common in	secondary malignancies
neutropenia	common in	secondary malignancies
bone marrow fibrosis	observed in	secondary malignancies
chromosomal abnormality	detected in	therapy-related AML
secondary malignancies surveillance	includes	complete blood count
secondary malignancies surveillance	includes	imaging studies
survivorship program	includes	secondary malignancies screening
family history	informs	secondary malignancies risk
genetic counseling	recommended for	families with secondary malignancies
chemotherapy dose	correlated with	secondary malignancies risk
radiation dose	correlated with	secondary malignancies risk
donor lymphocyte infusion	associated with	secondary malignancies
autologous transplant	followed by	secondary malignancies
allogeneic transplant	followed by	secondary malignancies
solid tumor	may become	second primary malignancy
pediatric cancer survivors	at risk for	secondary malignancies
adult cancer survivors	at risk for	secondary malignancies
radiation exposure	induces	secondary malignancies
alkylating agents	cause	secondary malignancies
topoisomerase II inhibitors	cause	secondary malignancies
immunosuppressive therapy	causes	secondary malignancies
chemotherapy	causes	secondary malignancies
radiation therapy	causes	secondary malignancies
hematologic malignancies	arise as	secondary malignancies
bone marrow biopsy	confirms	secondary malignancies
imaging studies	monitors	secondary malignancies
bone marrow aspirate	analyzes	secondary malignancies
central nervous system involvement	accompanies	secondary malignancies
second primary malignancy	incidence	rate
cancer therapy	leads to	secondary malignancies
genomic instability	promotes	secondary malignancies
host immune status	influences	secondary malignancies
age distribution	shows	secondary malignancies
survivor follow-up	includes	secondary malignancies surveillance
chromosomal instability	associated with	secondary malignancies
host factors	influence	secondary malignancies risk
long-term follow-up	addresses	secondary malignancies surveillance
medical surveillance	aims at	secondary malignancies detection
oncology care	includes	secondary malignancies monitoring
risk assessment	informs	secondary malignancies prevention
secondary malignancies	present with	cytopenias
secondary malignancies	present with	fatigue
secondary malignancies	present with	fever
secondary malignancies	present with	weight loss
secondary malignancies	present with	night sweats
secondary malignancies	present with	lymphadenopathy
secondary malignancies	present with	hepatomegaly
secondary malignancies	present with	splenomegaly
secondary malignancies	present with	bone pain
secondary malignancies	present with	bone lesions
secondary malignancies	present with	skin lesions
secondary malignancies	present with	oral lesions
secondary malignancies	present with	neurological symptoms
screening guidelines	recommend	secondary malignancies screening
current guidelines	recommend	secondary malignancies surveillance
